 So the company didn't see a way to have an adequate return on investment and saw better commercial value actually taking it into autoimmune diseases like rheumatoid arthritis. Explain why someone would need that endpoint, why the pharmaceutical industry would need that endpoint changed for a new therapy to be worth the cost to pharmaceutical drug developers.